Literature DB >> 25903416

Current and Emerging Treatment Options in Diabetes Care.

Christoffer Clemmensen1,2, Timo D Müller1,2, Brian Finan1,2, Matthias H Tschöp3,4, Richard DiMarchi5.   

Abstract

Diabetes constitutes an increasing threat to human health, particularly in newly industrialized and densely populated countries. Type 1 and type 2 diabetes arise from different etiologies but lead to similar metabolic derangements constituted by an absolute or relative lack of insulin that results in elevated plasma glucose. In the last three decades, a set of new medicines built upon a deeper understanding of physiology and diabetic pathology have emerged to enhance the clinical management of the disease and related disorders. Recent insights into insulin-dependent and insulin-independent molecular events have accelerated the generation of a series of novel medicinal agents, which hold the promise for further advances in the management of diabetes. In this chapter, we provide a historical context for what has been accomplished to provide perspective for future research and novel emerging treatment options.

Entities:  

Keywords:  Co-agonist; Combination therapies; Diabetes; Glucose; Insulin; Metabolism; Obesity; Pharmacology; Therapeutics

Mesh:

Substances:

Year:  2016        PMID: 25903416     DOI: 10.1007/164_2015_7

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  7 in total

1.  Small extracellular vesicle-mediated targeting of hypothalamic AMPKα1 corrects obesity through BAT activation.

Authors:  Edward Milbank; Nathalia R V Dragano; Ismael González-García; Marcos Rios Garcia; Verónica Rivas-Limeres; Liliana Perdomo; Grégory Hilairet; Francisco Ruiz-Pino; Patricia Mallegol; Donald A Morgan; Ramón Iglesias-Rey; Cristina Contreras; Luisa Vergori; Juan Cuñarro; Begoña Porteiro; Aleix Gavaldà-Navarro; Rebecca Oelkrug; Anxo Vidal; Juan Roa; Tomás Sobrino; Francesc Villarroya; Carlos Diéguez; Rubén Nogueiras; Cristina García-Cáceres; Manuel Tena-Sempere; Jens Mittag; M Carmen Martínez; Kamal Rahmouni; Ramaroson Andriantsitohaina; Miguel López
Journal:  Nat Metab       Date:  2021-10-21

Review 2.  Gut-Brain Cross-Talk in Metabolic Control.

Authors:  Christoffer Clemmensen; Timo D Müller; Stephen C Woods; Hans-Rudolf Berthoud; Randy J Seeley; Matthias H Tschöp
Journal:  Cell       Date:  2017-02-23       Impact factor: 41.582

Review 3.  EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?

Authors:  Miguel López
Journal:  Eur J Endocrinol       Date:  2017-02-23       Impact factor: 6.664

4.  Lorcaserin improves glycemic control via a melanocortin neurocircuit.

Authors:  Luke K Burke; Emmanuel Ogunnowo-Bada; Teodora Georgescu; Claudia Cristiano; Pablo B Martinez de Morentin; Lourdes Valencia Torres; Giuseppe D'Agostino; Christine Riches; Nicholas Heeley; Yue Ruan; Marcelo Rubinstein; Malcolm J Low; Martin G Myers; Justin J Rochford; Mark L Evans; Lora K Heisler
Journal:  Mol Metab       Date:  2017-07-21       Impact factor: 7.422

Review 5.  GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH.

Authors:  Qiu-Xuan Li; Han Gao; Yue-Xin Guo; Bo-Ya Wang; Rong-Xuan Hua; Lei Gao; Hong-Wei Shang; Xin Lu; Jing-Dong Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

Review 6.  The impact of ERα action on muscle metabolism and insulin sensitivity - Strong enough for a man, made for a woman.

Authors:  Andrea L Hevener; Zhenqi Zhou; Timothy M Moore; Brian G Drew; Vicent Ribas
Journal:  Mol Metab       Date:  2018-06-21       Impact factor: 8.568

Review 7.  Hypothalamic AMPK and energy balance.

Authors:  Miguel López
Journal:  Eur J Clin Invest       Date:  2018-07-30       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.